AgomAb Therapeutics NV (NASDAQ:AGMB) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of AgomAb Therapeutics NV (NASDAQ:AGMB) have been given a consensus recommendation of “Moderate Buy” by the eight research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $37.50.

Several research firms recently issued reports on AGMB. Wall Street Zen lowered AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Piper Sandler initiated coverage on AgomAb Therapeutics in a research report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 target price for the company. B. Riley Financial began coverage on shares of AgomAb Therapeutics in a research note on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target on the stock. Cantor Fitzgerald began coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating on the stock. Finally, HC Wainwright began coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 price objective for the company.

AgomAb Therapeutics Price Performance

Shares of NASDAQ AGMB opened at $15.78 on Friday. The business’s 50 day moving average is $13.35 and its two-hundred day moving average is $12.51. AgomAb Therapeutics has a 52-week low of $8.75 and a 52-week high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. Sell-side analysts expect that AgomAb Therapeutics will post -1.76 EPS for the current fiscal year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.